Cosmo Pharmaceuticals N.V. Profit Margin

The latest profit margin for COPN.SW is 17.16% as of June 2026. That compares with 27.77% in the prior-year period — down 38.2% year over year. That is above the sector sector average of 13.78%. Investors often review this figure alongside Cosmo Pharmaceuticals N.V.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, COPN.SW's profit margin moved from 27.77% to 17.16% — a 38.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cosmo Pharmaceuticals N.V.'s valuation or profitability profile.

Against its sector companies, COPN.SW currently prints 17.16% for profit margin, while the sector average sits near 13.78%. That is roughly 24.5% above the sector mean. Large gaps often invite a closer look at Cosmo Pharmaceuticals N.V.'s growth, margins, and balance sheet.

Profit Margin shows how effectively Cosmo Pharmaceuticals N.V. converts resources into returns. At 17.16%, COPN.SW may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 27.77% in the prior-year period — down 38.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting COPN.SW's profit margin (17.16%), review year-over-year change from 27.77%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.